Oncology News | pharmaphorum

News

Radiology technician examens mammography test on location

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer ...

The European Commission has cleared AstraZeneca and Merck & Co's Lynparza as an adjuvant treatment for breast cancer, extending its lead over would-be rivals in the PARP inhibitor class

News

Gilead Sciences' push into oncology is paying off, as Veklur...

Gilead Sciences' investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first time in the second quarter.<

News

Roche adds to pipeline with Poseida, Kiniksa deals

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases.

News

Phase 3 lung cancer fail dents prospects of Ipsen, Servier's...

Ipsen and Servier's hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cance

News

Doctor in white rubber protective gloves putting adhesive bandage on young man's arm after scratch on skin or injection of vaccine. First aid. Medical, pharmacy and healthcare concept. Closeup.

Roche scores phase 3 win for subcutaneous Tecentriq, eyes fi...

Roche's Tecentriq could become the first drug in the PD-1/PD-L1 inhibitor class to be approved in a subcutaneous formulation, after the new version matched the original intravenous formulat

News

Ipsen makes TCR play, grabbing two I-O therapies from Mareng...

Ipsen has joined the ranks of companies working on T cell receptor (TCR) therapies for cancer, paying $45 million upfront for rights to early-stage candidates developed by US biotech Mareng

AZ, Merck get EU nod for Lynparza as adjuvant breast cancer ...

Gilead Sciences' push into oncology is paying off, as Veklur...

Roche adds to pipeline with Poseida, Kiniksa deals

Phase 3 lung cancer fail dents prospects of Ipsen, Servier's...

Roche scores phase 3 win for subcutaneous Tecentriq, eyes fi...

Ipsen makes TCR play, grabbing two I-O therapies from Mareng...

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks